Current SCD Studies (3):
• CSL889 - A 2-Part, Phase 1, Multicenter, Single-Dose, Open- Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients with Sickle Cell Disease. • The study includes 2 parts . • Part A : To evaluate single dose administration of CSL889 in subjects with stable SCD • Part B : To evaluate single dose administration of CSL889 in subjects with SCD in VOC.
Made with FlippingBook Digital Proposal Creator